Collaborators

University of Rhode Island (URI)

The University of Rhode Island is the State’s public learner-centered research university. We are a community joined in a common quest for knowledge. The University is committed to enriching the lives of its students through its land, sea, and urban grant traditions. URI is the only public institution in Rhode Island offering undergraduate, graduate, and professional students the distinctive educational opportunities of a major research university. (uri.edu)

Epivax

EpiVax, Inc. was founded by Anne De Groot, M.D. in 1998 and is based in Providence, RI. Epivax, Inc. manages the EpiMatrix vaccine design technology that was licensed by De Groot. Bill Martin serves as Epivax’s Chief Information Officer and Chief Operating Officer, and he is the principal architect and developer of the EpiMatrix System. (epivax.com)

National Institutes of Health (NIH)

NIH is the nation’s medical research agency – making important medical discoveries that improve health and save lives. The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the primary Federal agency for conducting and supporting medical research. (nih.gov)

Centers for Disease Control and Prevention (CDC)

CDC collaborates to create the expertise, information, and tools that people and communities need to protect their health – through health promotion, prevention of disease, injury and disability, and preparedness for new health threats. CDC seeks to accomplish its mission by working with partners throughout the nation and the world. (cdc.gov)

Dana-Farber Cancer Institute

Dana-Farber is committed to providing cancer patients with the best treatment available today while developing tomorrow’s cures through cutting-edge research. The mission of Dana-Farber Cancer Institute is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases. (dana-farber.org)

Cooperative Centers for Translational Research on Human Immunology (CCHI)

The long-term goal of the Cooperative Centers for Translational Research on Human Immunology and Biodefense (CCHI) program is the translation of research into clinical applications in humans. The immediate goals are to support basic and translational research on human immunological responses to NIAID Category A, B or C priority pathogens, their toxins, or other emerging or re-emerging infectious diseases; and to maintain the stable, flexible, and centralized infrastructure needed to promote and coordinate multi-disciplinary research in human immunology as it relates to defense against these agents. The CCHI program was established in 2003 by the NIAID Division of Allergy, Immunology and Transplantation as part of the overall NIAID biodefense effort. The renewal of this program maintains NIAID’s commitment in this effort through continuing support for cooperative immunology centers focused on the translation of research from animals to humans. (humanimmunology.org)